Article Text

Download PDFPDF

#980 MLH1 promoter hypermethylated endometrial cancer: clinical and molecular characteristics from a retrospective cohort
  1. Narda Kebaier Ep Chaabouni1,
  2. Paula Proszek2,
  3. Liam Johnson2,
  4. Michaela Smalley2,
  5. Ridwan Shaikh2,
  6. Katherine Vroobel1,
  7. Ayoma Attygalle1,
  8. Susan Lalondrelle1,3,
  9. Alexandra Taylor1,3 and
  10. Angela George1
  1. 1Gynaecology Unit, The Royal Marsden Foundation Trust, London, UK
  2. 2Clinical Genomics, The Royal Marsden Foundation Trust, London, UK
  3. 3The Institute of Cancer Research, London, UK


Introduction/Background MLH1 promoter hypermethylation is common in sporadic microsatellite unstable endometrial cancer but data on MLH1 promoter hypermethylated endometrial cancer (MLH1-PM EC) is sparse. We aimed to identify the clinical and molecular characteristics of MLH1-PM EC.

Methodology Descriptive analysis of 246 tumours from patients treated between September 2007 to June 2022. Mismatch repair proteins (MMR) were tested by immunohistochemistry (IHC). Tumour specimens were sequenced using the Royal Marsden RMH200Solid panel which includes 233 genes and evaluates microsatellite instability (MSI) and tumour mutational burden (TMB). Droplet Digital PCR (ddPCR) was used for DNA methylation analysis in each case. Patients’ characteristics were recorded from our electronic records.

Results MLH1-PM was identified in 71/246 tumours (28.9%): 61 were MMRd and 10 MMR proficient by IHC. The most common protein loss was MLH1/PMS2 in 57/61 cases (93.5%). Isolated loss of MSH6 was present in 3 cases and MSH2/MSH6 loss in 1 case. MLH1-PM tumours were MSI high in 47/71 (66.2%) of cases with a mean TMB of 30.96 mut/mb (12.21–193.93) and MSS in 24/71 (33.8%) of cases with a mean TMB of 48.65 mut/mb (0–231.91). The predominant histological subtype was endometrioid (n=64). Most tumours were stage I or II at diagnosis (n=55). Mean age at diagnosis was 65 years (32–90) and mean body mass index (BMI) was 31.64 (17.3–53.9). 14/71 (19.7%) patients presented with relapsed disease after initial diagnosis: loco-regional in 4 cases and systemic in 10 cases. Genomic analysis revealed that MLH1-PM ECs were enriched in PTEN, ARID1A, PIK3CA, KMT2D, KMT2C, PIK3R1, KRAS, FAT1, BCOR and ATM mutations. In patients who relapsed (n=14), gain of chromosome 1q was identified in 7 cases (50%).

Conclusion MLH1-PM EC is found in 30% of unselected EC patients and harbors genomic alterations that may have potential prognostic and therapeutic implications. Further studies are needed to develop appropriate treatment strategies.

Disclosures Dr. Alexandra Taylor: MSD.

Dr. Angela George : Astra Zeneca, GSK, Roche, Merck.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.